Business
MicroBlate™ Fine commercial update
Creo Medical Group plc has provided a commercial update on its MicroBlate Fine precision microwave ablation platform, announcing over 50 clinical cases globally and significant US adoption, including the first EUS-guided microwave ablation of a pancreatic lesion. This development, powered by Creo's CROMA Advanced Energy Platform, is expected to accelerate market acceptance and recurring revenues, particularly in the large US therapeutic endoscopy market, with continued site expansion anticipated throughout 2026. Disclaimer*
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n\n\n \nCreo Medical Group plc\n(\"Creo\", the \"Company\" or the \"Group\")\n \nMicroBlate™ Fine commercial update\nCreo Medical accelerates US clinical adoption and commercial rollout of MicroBlate Fine\nFirst breakthrough case delivering targeted therapy for pancreatic lesions\n \nCreo Medical Group plc (AIM: CREO), the medical device company specialising in advanced energy solutions for therapeutic endoscopy, announces a clinical and commercial update on MicroBlate Fine, its precision microwave ablation platform, as momentum builds across early US clinical adoption and commercial rollout.\n \nMicroBlate Fine has now crossed the threshold of 50 clinical cases worldwide across multiple institutions, with particularly strong engagement from leading US interventional endoscopy centres. MicroBlate Fine is being further evaluated through an international investigator‑led study across the US, Europe and Asia‑Pacific, with Banner Health in the US acting as the principal investigative site. The study is targeting patients with pancreatic and liver lesions. The first patient was treated in March 2026.\n \nIn the US, MicroBlate Fine has recently been used to perform the first endoscopic ultrasound (\"EUS\") guided microwave ablation of a pancreatic lesion, highlighting its applicability in complex and previously difficult‑to‑treat anatomy. MicroBlate Fine enables EUS‑guided microwave ablation through a flexible 19G needle, providing precise, controlled and homogeneous energy delivery while integrating seamlessly into existing EUS workflows. The device is powered by Creo's CROMA™ Advanced Energy Platform.\n \nEarly adoption by US centres of excellence plays a critical role in accelerating broader market acceptance and supports future commercial scale‑up in what represents one of the world's largest therapeutic endoscopy markets. MicroBlate Fine provides a strategic entry point into high‑value microwave ablation procedures, with the potential to enhance recurring revenues and increase utilisation of Creo's broader advanced energy ecosystem, particularly in the US market.\n \nThe Company expects continued expansion of site adoption through 2026, alongside growing US clinical engagement, supporting both near‑term revenue generation and longer‑term market penetration in advanced therapeutic endoscopy.\n&n...